Skip to main content

Table 2 Treatment outcomes of cetuximab therapy and the corresponding number of patients

From: Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan

Treatment outcomes

Number of patients N (%)

Response

 Complete response

0 (0.0)

 Partial response

21 (36.2)

 Stable disease

9 (15.5)

 Progressive disease

28 (48.3)

 Response rate

21 (36.2)

 Disease control rate

30 (51.7)